Summary

For a classification of systemic lupus erythematosus (SLE), patients must have at least one clinical and one immunologic criterion of the SLICC classification criteria, for a total of four, or must have biopsy-proven lupus nephritis. This article discusses prednisone for the treatment of SLE, the treatment of severe thrombocytopenia in SLE, severe cutaneous manifestations in patients with SLE, as well as subtypes of posterior reversible leukoencephalopathy syndrome, myelitis, and small-fiber neuropathies in SLE.